CD19 and B-cell chronic lymphocytic leukemia: Patients with CLL had significantly decreased levels of CD19+IgM−IgD+ B cells (17.49 ± 8.22) when compared to the control group (28.22 ± 28.22), p = 0.0170 (Fig. 2A).